Approach of the snapping hip syndrome that can be divided as intra-articular and extra-articular causes.
\r\n\t
",isbn:"978-1-83969-234-5",printIsbn:"978-1-83969-233-8",pdfIsbn:"978-1-83969-235-2",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,hash:"a5f5277a1c0616ce6b35f4b44a4cac7a",bookSignature:"Dr. Basel I. Ismail",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10013.jpg",keywords:"Thermodynamics, Heat Transfer Analyses, Geothermal Power Generation, Economics, Geothermal Systems, Geothermal Heat Pump, Green Energy Buildings, Exploration Methods, Geologic Fundamentals, Geotechnical, Geothermal System Materials, Sustainability",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 29th 2020",dateEndSecondStepPublish:"November 26th 2020",dateEndThirdStepPublish:"January 25th 2021",dateEndFourthStepPublish:"April 15th 2021",dateEndFifthStepPublish:"June 14th 2021",remainingDaysToSecondStep:"2 months",secondStepPassed:!0,currentStepOfPublishingProcess:3,editedByType:null,kuFlag:!1,biosketch:"Leading research investigator in a collaborative project (2007-2010) with Goldcorp-Musselwhite Canada Ltd. and Engineering of Lakehead University, owner of a Ph.D. degree in Mechanical Engineering from McMaster University, Hamilton, Ontario, Canada and postdoctoral researcher (2004 to 2005) at McMaster University.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"62122",title:"Dr.",name:"Basel",middleName:"I.",surname:"Ismail",slug:"basel-ismail",fullName:"Basel Ismail",profilePictureURL:"https://mts.intechopen.com/storage/users/62122/images/system/62122.jpg",biography:"Dr. B. Ismail is currently an Associate Professor and Chairman of the Department of Mechanical Engineering, Lakehead University, Thunder Bay, Ontario, Canada. In 2004, Prof. Ismail earned his Ph.D. degree in Mechanical Engineering from McMaster University, Hamilton, Ontario, Canada. From 2004 to 2005, he worked as a Postdoctoral researcher at McMaster University. His specialty is in engineering heat transfer, engineering thermodynamics, and energy conversion and storage engineering. Dr. Ismail’s research activities are theoretical and applied in nature. Currently, his research areas of interest are focused on green engineering technologies related to alternative and renewable energy systems for power generation, heating and cooling. Dr. Ismail was the leading research investigator in a collaborative project (2007-2010) with Goldcorp-Musselwhite Canada Ltd. and Engineering of Lakehead University. This innovative project was state-of-the-art in geothermal heat pump technology applied in Northwestern Ontario, Canada. Dr. Ismail has published many technical reports and articles related to his research areas in reputable International Journals and Conferences. During his research activities, Dr. Ismail has supervised and trained many graduate students and senior undergraduate students in Mechanical Engineering with projects and theses related to innovative renewable and alternative energy engineering, and technologies.",institutionString:"Lakehead University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"4",totalChapterViews:"0",totalEditedBooks:"3",institution:{name:"Lakehead University",institutionURL:null,country:{name:"Canada"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"11",title:"Engineering",slug:"engineering"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"184402",firstName:"Romina",lastName:"Rovan",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/184402/images/4747_n.jpg",email:"romina.r@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"5084",title:"Advances in Geothermal Energy",subtitle:null,isOpenForSubmission:!1,hash:"d4647f1f9dae170acf327283d55abbf1",slug:"advances-in-geothermal-energy",bookSignature:"Basel I. Ismail",coverURL:"https://cdn.intechopen.com/books/images_new/5084.jpg",editedByType:"Edited by",editors:[{id:"62122",title:"Dr.",name:"Basel",surname:"Ismail",slug:"basel-ismail",fullName:"Basel Ismail"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5602",title:"Renewable Hydropower Technologies",subtitle:null,isOpenForSubmission:!1,hash:"15ea891d96b6c9f2d3f28d5a21c09203",slug:"renewable-hydropower-technologies",bookSignature:"Basel I. Ismail",coverURL:"https://cdn.intechopen.com/books/images_new/5602.jpg",editedByType:"Edited by",editors:[{id:"62122",title:"Dr.",name:"Basel",surname:"Ismail",slug:"basel-ismail",fullName:"Basel Ismail"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7504",title:"Renewable Geothermal Energy Explorations",subtitle:null,isOpenForSubmission:!1,hash:"d47d551b0fcf11a4328c8a38f2499844",slug:"renewable-geothermal-energy-explorations",bookSignature:"Basel I. Ismail",coverURL:"https://cdn.intechopen.com/books/images_new/7504.jpg",editedByType:"Edited by",editors:[{id:"62122",title:"Dr.",name:"Basel",surname:"Ismail",slug:"basel-ismail",fullName:"Basel Ismail"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"71604",title:"Arthroscopic and Endoscopic Management of the Internal Snapping Hip Syndrome",doi:"10.5772/intechopen.91919",slug:"arthroscopic-and-endoscopic-management-of-the-internal-snapping-hip-syndrome",body:'\nSnapping hip syndrome or coxa saltans is an abnormal hip condition that includes a painful popping sensation and sound with movement around the hip joint. In the general population, snapping hip can be found in about 5–10% and for most are asymptomatic. Snapping hip syndrome can be divided as intra-articular and extra-articular snapping as seen in Table 1.
\nIntra-articular snapping | \nExtra-articular snapping | \n
---|---|
Soft tissue \n
\n
| \nAnterior or internal \n
\n
| \n
Approach of the snapping hip syndrome that can be divided as intra-articular and extra-articular causes.
Internal snapping hip syndrome is snapping hip caused by the iliopsoas tendon migrating over the superior pubic ramus, iliopectineal eminence, anterior hip joint, femoral head or the lesser trochanter. Multiple or bifid iliopsoas tendons can also be found during transcapsular iliopsoas release in about 17.85% of cases [1].
\nSigns and symptoms include pain or a popping sensation in the area near the anterior groin. The clicking or popping sensation can be reproduced by allowing the patient to perform active hip extension and/or external rotation in a flexion position of the hip (Figure 1). Some patients present with a positive C-sign at the painful area. The patients may have focal tenderness over the iliopsoas (anterior groin) and a positive impingement test (Flexion-Adduction-Internal Rotation test, FADIR test) either with or without concomitant femoroacetabular impingement syndrome.
\nThe internal snapping test is performed by letting the patient performs active hip extension and/or external rotation from the starting flexion position of the examined hip. Positive result when the clicking or popping sensation can be reproduced.
The resisted straight leg raise (RSLR) test is performed by the patient flexing the hip actively at approximately 30° in full knee extension. The examiner places a hand just above the patient’s knee to resist hip flexion in that position (Figure 2). A positive result is when there is pain at the anterior groin or weakness in the hip flexion that represents iliopsoas problems or intra-articular pathologies [2].
\nThe resisted straight leg raise (RSLR) test is performed by allowing the patient flex to the hip actively to approximately 30° in a full knee extension, the examiner places a hand just above the patient’s knee to resist hip flexion in that position. Positive result when pain or weakness represents iliopsoas pathology or intra-articular causes.
The investigations include plain radiographs of the pelvis/hip that might be helpful in ruling out other causes of hip pain or detecting associated pathologies that can affect the hip joint. MRI of the affected hip could aid in ruling out others causes of hip pain or detect associated pathologies, particularly, an anterior labral lesion. Some studies showed the correlation of a 3 O’clock positioned labral tear/injury with iliopsoas impingement by the friction of the iliopsoas tendon to the predominately, anterior portion of the labrum caused tear [3, 4]. Dynamic ultrasonography is useful to detect snapping of the iliopsoas during actual hip motion and can be conjugate with an ultrasound-guided bursal injection. In iliopsoas impingement, the pain could be improved after an iliopsoas bursal injection rather than an intra-articular injection of anesthetic agents [4].
\nNowadays, total hip replacements (THR) are increasing in numbers and indications [5]. An iliopsoas impingement can be a complication of this procedure from impingement of the iliopsoas tendon with the acetabular component [6, 7] (Figure 3). This is noticeable in the large size of the acetabular components or in patients with dysplastic morphology of the native hip associated with under coverage of the anterior/superior acetabular rim.
\nA lateral cross table radiograph of the left hip following total hip arthroplasty demonstrates the anterior overhang of the acetabular component (red circle) at about 5 mm, leading to iliopsoas impingement.
Conservative management of internal snapping hip syndrome includes rest, activity modification, anti-inflammatory medications, injections of a local anesthetic combined with a corticosteroid into the involved bursa or around the tendon sheath and the stretching of the iliopsoas (Figure 4).
\nDemonstrate the stretching method of the right iliopsoas muscle/tendon. The affected hip is extended during controlled trunk balancing.
The surgical treatment consists of iliopsoas release via an open, arthroscopic or endoscopic approach with or without intra-articular procedures. In the total hip replacement patient with obvious acetabular component malposition or prominence, acetabular cup revision maybe necessary [6]. For the arthroscopic/endoscopic iliopsoas release techniques, these can be performed using: 1. the transcapsular release (proximal arthroscopic release) via the central or peripheral compartment and 2. releasing at the lesser trochanteric level (distal endoscopic release) (Figure 5).
\nDemonstration of the iliopsoas release techniques: (A) proximal arthroscopic transcapsular release via a central compartment approach; (B) proximal arthroscopic transcapsular release via a peripheral compartment approach; and (c) distal endoscopic release at the lesser trochanteric level.
In this chapter, two common iliopsoas release procedures will be presented. The contents of indications, patients positioning, arthroscopic/endoscopic portals and the details of procedures are described. The evidence-based reviews of the procedures will also be presented.
\n\n
Internal snapping hip syndrome with failed conservative treatments for more than 4–6 months.
Conjugate with the arthroscopic procedure of the hip (such as anterior labral repair).
The iliopsoas release could be performed using the supine or lateral decubitus position. The author’s preferred patient position is supine on a traction radiolucent table (Maquet, Rastatt, Germany). Both legs and feet are well padded and wrapped with soft cotton and hung on the footplate. A large, well-padded perineal post is used to prevent complications from pudendal nerve compression. The C-arm is placed at the non-operative side and positioned horizontally to check the anteroposterior view of the affected hip. Traction is performed to check the possibility of central compartment assess and intra-articular arthroscopic work.
\nThe peripheral compartment approach is introduced in hip flexion of 20–30° using a proximal anterolateral portal (PAL). Peripheral compartment examination and synovectomy are performed using an anterior working portal (Figure 6). Following the peripheral compartment work that includes synovectomy and cam resection, the central compartment is assessed under traction of the hip in a full extension position. Intra-articular examination and surgical procedures are completely performed. These include; debridement, acetabuloplasty, and labral surgery.
\nThe portals used in peripheral compartment approach of the right hip. Proximal anterolateral portal (PAL) is the start and viewing portal. Anterior (A) and anterolateral (AL) portals are shown. GT, greater trochanter; ASIS, anterior superior iliac spine.
The arthroscopic iliopsoas tenotomy can performed by two methods: (1) central compartment approach under traction and (2) peripheral compartment approach with hip flexion of 20–30°.
\nIn a central compartment approach. After performing the intra-articular procedures, the arthroscope is retracted to the peripheral compartment to assess under traction the anterior hip capsule at approximately the 3 O’clock position of the anterior labrum. This step uses the anterolateral viewing portal and the anterior portal for the procedure. Inflammation of the anterior labrum may represent evidence of iliopsoas impingement. The iliopsoas tendon is located near the anteromedial aspect of the anterior hip capsule. The anterior capsule at this area is thin and some patients have an anterior capsular hole directly connected to the iliopsoas tendon [8]. A capsulotomy of approximately 1–2 cm is performed to the 3 O’clock position of the right hip. After capsulotomy, the synovial tissue around the iliopsoas tendon is identified and resected using an arthroscopic shaver or electrocautery. The iliopsoas tendon is identified and released until the iliacus muscle can be observed beneath the released portion of the tendon. Keeping this portion of the iliacus muscle may decrease of the risk of hip flexion weakness, postoperatively (Figure 7).
\nArthroscopic view of the central compartment transcapsular iliopsoas tenotomy of the right hip. (A and B) Peripheral compartment first approach using the proximal anterolateral (PAL) viewing portal and anterior working portal. (C and D) Approach to the central compartment by direct visualization and inserting the switching stick through the anterior portal. (E and F) Examination in the central compartment. (G) Create the anterolateral (AL) portal under direct visualization using anterior viewing portal. (H and I) Switch the scope to the AL viewing portal and working from the anterior portal. (J to L) After a small anterior capsulotomy to about the 3 O’clock position, the iliopsoas tendon (IP) is cut using electrocautery. The iliacus muscle (*) is preserved. [L-labrum, FH-femoral head, FN-femoral neck, A-acetabulum, C-capsule].
In the peripheral compartment approach, following the intra-articular work, the traction is released to reduce the hip joint. The arthroscope is inserted via the same AL viewing portal or re-inserted from the PAL portal in the hip at 20–30° in a flexion position. Then, the zona orbicularis, medial synovial fold, and the anterior labrum are identified. The medial synovial fold is the landmark for the most inferomedial head–neck area, also known as, the 6 O’clock position. The 1–2 cm capsulotomy is performed at the capsular space between the anterior labrum and the zona orbicularis close to the proximal attachment of the medial synovial fold. After capsulotomy, the synovial tissue around the iliopsoas tendon is resected as previously described and the iliopsoas tendon is released while preserving the iliacus muscle.
\nIt is not necessary to perform the capsular closure if the capsulotomy is less than 1–2 cm. With complete tenotomy of the iliopsoas, either in the central or peripheral approach, the portals are sutured simple and the wounds are closed in standard fashion.
\nActive hip range of motion is allowed immediately post operatively. The hip flexion strength may decrease in the first 6 to 8 weeks and usually restores after 8 weeks. Active hip flexor strengthening exercises are allowed after 6 weeks postoperatively.
\nWeight bearing is dependent on the intra-articular conditions. The patients apply partial weight bearing for 6 weeks if the cartilage or the labral lesions were repaired/fixated, or if osteochondroplasty of the cam lesion is done. In the isolated iliopsoas release patients, there is no need to protect weight bearing after post operatively. Return to sport activities are allowed after 3 months.
\n\n
Painful iliopsoas impingement following a total hip replacement, no obvious malposition of the acetabular cup and the anterior overhang is <8 mm.
Failed conservative more than 4–6 months with positive iliopsoas injection test.
No evidence of prosthesis loosening or infection.
Preoperative physical examination, blood analysis for white blood cell count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), hip X-rays, and CT assessment are needed to evaluate possible other causes of hip/groin pain in total hip replacement patients. Infection and prosthesis loosening need to be ruled out.
\nThe author’s preferred patient position is supine on a radiolucent traction table (Maquet, Rastatt, Germany) similar for the patient with an arthroscopic proximal release. Both legs and feet are well padded, wrapped with soft cotton and hung to the footplate. A large, well-padded perineal post is used to prevent complications from pudendal nerve compression. The C-arm is placed at the non-operative side and positioned horizontally to check the anteroposterior view of the affected hip. Traction of the prosthetic component is not a requirement and the release is performed at the lesser trochanter level. The affected leg is placed in an externally rotated position of the hip in full knee extension. This moves the lesser trochanter further anteriorly (Figure 8).
\nPatient positioned for the endoscopic iliopsoas release of the left hip. Supine on the radiolucent traction table. The surgical hip is in external rotation, fully stretched in full knee extension that brings the lessor trochanter further anteriorly.
The endoscopic portals are marked as seen in Figure 9. The anterolateral portal (1–2 cm anterior to level of tip of greater trochanter) and distal anterolateral portal (5–7 cm distal to anterolateral portal) are identified. The direction of the instrument and arthroscope can be aligned under fluoroscopic control toward the tip of the lesser trochanter (Figure 10). The needle and guidewire are inserted through the anterolateral portal with the designed trajectory toward the lesser trochanter. A 4.5-mm cannulated switching-stick (Smith and Nephew, MA, USA) is inserted then changed to a 5.0-mm cannula and an obturator. Blunt dissection using the cannula is performed above the lesser trochanter in a superior-inferior direction to create more working space anteriorly under fluoroscopic guidance. A 70° arthroscope is inserted via this anterolateral portal and the distal anterolateral portal is created as a second portal using a needle and guidewire under fluoroscopy. The 4.5-mm, cannulated switching stick is inserted through the guidewire under endoscopic control. The iliopsoas tendon is identified at the lesser trochanteric insertion then, the radiofrequency or an arthroscopic shaver is used via the distal anterolateral portal to remove the iliopsoas bursa surrounding the tendon and to obtain adequate visualization of the tendon. The iliopsoas tendon is ‘peeled’ from the lesser trochanter using radiofrequency under direct vision (Figure 11). After completion of the tenotomy, the portals are simply sutured, and the wounds are closed in standard fashion.
\nEndoscopic portals of the left hip in supine position without traction. Left hand is patient’s up and right is the legs. AL, anterolateral portal; DAL, distal anterolateral portal; ASIS, anterior superior iliac spine; GT, greater trochanter.
Demonstration of the direction of the instrument and endoscope under fluoroscopic control in a left, prosthetic hip: (A) both instruments aimed toward tip of the lessor trochanter in the convergence direction. (B) and (C)the endoscope is inserted from the AL portal and the radiofrequency abrasion is inserted from the DAL portal.
Endoscopic view from the anterolateral portal of the left hip; right is the proximal aspect and left is the distal aspect of the proximal femur: (A) and (B) identification of the anterior femoral cortex, iliopsoas bursa (IP bursa) and lessor trochanter (LT) using the distal anterolateral working portal; (C) identification of the iliopsoas tendon (IP) which attaches to the lessor trochanter; (D) peeled-off iliopsoas tendon from the lessor trochanter using radiofrequency; and (E) and (F) lessor trochanter and the surrounding tissue after the iliopsoas tendon release.
Active hip range of motion exercises are allowed immediately following surgery. Hip flexion strength may decrease in the first 6–8 weeks and usually returns to baseline after 8 weeks. Active hip flexor strengthening exercises are allowed after 6 weeks postoperative. The patients progress to full weight bearing as soon as possible, postoperatively. Return to normal activities is allowed 6–8 weeks after surgery.
\nAn iliopsoas tenotomy has shown good to excellent postoperative outcomes in indicated patients with iliopsoas snapping/impingement. The systematic reviews of 11 eligible studies (248 patients), level IV studies revealed ‘the resolution of snapping’ as seen in 100% of patients who underwent an arthroscopic release and 77% of those who underwent open procedures. The complication rates were higher in patients undergoing an open procedure (21%) compared with an arthroscopic procedure (2.3%). The analysis of the open procedure; either open transection of the iliopsoas tendon at the level of the lesser trochanter (14 patients) or open tendon lengthening of the iliopsoas tendon (105 patients) has shown 27 of 119 patients with recurrence of snapping and 4 of 119 experienced snapping with pain, 6 patients needed a second surgical intervention. There was an increased prevalence of recurrent snapping with open transection of the iliopsoas tendon as compared to patients with iliopsoas tendon lengthening (43% vs. 20%). The complications of the open procedure are postoperative pain (11–36%) and the hip flexion weakness (8–14%). In the arthroscopic group with transection at the lesser trochanter and transcapsular release, 3 of 37 (8%) patients of the group with transection at lesser trochanter reported complications including 2 cases of ischial bursitis and 1 case of greater trochanteric bursitis. No reported complications from the transcapsular release group. No hip flexion weakness was reported in the arthroscopic groups. None of the arthroscopically treated patients required a second surgical intervention [9].
\nA study of 25 patients with 2-year follow up following transcapsular release with intra-articular procedures in the internal snapping hip with combined pathologies revealed 88% of patients with good to excellent results without serious complications [10]. A comparative case-series with 20 patients, including 6 patients with a release at the lesser trochanter level vs. 14 central compartment release patients revealed the same favorable results based-on WOMAC scores. Just 1 of 14 patient with central compartment release had a recurrence of snapping that required surgical intervention. No complications were reported in both groups [11].
\nThe iliopsoas release/tenotomy is the treatment option for iliopsoas tendinopathy or impingement following a total hip replacement. A systematic review of level IV studies in 18 studies (11 case series, 6 case reports and 1 prospective cohort) of 171 patients who underwent hip arthroscopy after an arthroplasty revealed the pathology, including 35.8% of iliopsoas tendinopathy, 24.6% of symptomatic hips with no clear diagnosis, 6.4% of periprosthetic infection, and 3.5% of intra-articular loose bodies. Almost all patients who underwent hip arthroscopy experienced positive outcomes from the procedure [12]. A systematic review of 11 studies, 280 hips treated for iliopsoas impingement, following a total hip replacement, showed improved outcome scores in all three treatment groups including: 1. conservative treatment group (54 patients using local injections and physical therapy), 2. Iliopsoas tenotomy group (133 patients using either arthroscopic, endoscopic or an open approach), and 3. Revision arthroplasty (93 patients by exchange of the acetabular component). The tenotomy group reported 5 (3.76%) complications that included 1 patient with a 13-mm acetabular prominence with continuing groin pain and subsequently needed component revision, 1 patient with a heterotrophic ossification, 1 anterior dislocation, 1 compressive hematoma affecting the peroneal nerve, and 1 periprosthetic ossification. The revision arthroplasty group reported 18 (19.4%) complications including 5 developing trochanteric bursitis, 4 with recurrent groin pain, 2 revision surgeries, 2 dislocations, 1 DVT, 1 deep infection, 1 trochanteric nonunion, 1 superficial wound infection, and 1 disarticulation [13].
\nA retrospective review of 49 patients [6] who had been treated for iliopsoas impingement after a primary total hip arthroplasty with 4 years of mean follow-up show 50% (10 patients) in the nonoperative group had groin pain resolution as compared to 76% (22 patients) in the operative group (p = 0.06). The patients with <8 mm of component prominent tenotomy stated 100% resolution of groin pain (5 patients) but patients with ≥8 mm of prominent tenotomy led to groin pain resolution at only 33% (3 patients). Acetabular revision in patients with ≥8 mm of prominence had groin pain resolution in 92% (12 of 13 patients) (p = 0.07). Thus, it is suggested that use of tenotomy in patients with <8 mm of component prominence and acetabular revision in patients with ≥8 mm of prominence is indicated.
\nIliopsoas snapping is one of the causes of hip pain in either, native or prosthetic hips. The mainstay treatment is conservative management, especially, in iliopsoas stretching. The iliopsoas release is the definite treatment in failed conservative patients. Either arthroscopic iliopsoas release from the central/peripheral compartment or, endoscopic iliopsoas release at the lesser trochanter level have shown good to excellent results in the postoperative outcomes. Acetabular revision may be considered in patients with ≥8 mm of prominence with persistent groin pain following a total hip replacement.
\nThe author thanks the Orthopedics Department, Faculty of Medicine, Thammasat University and Thammasat University Hospital for the kind support. No funding was obtained regarding this manuscript.
\nThe authors declare no conflict of interest.
\n
Anemia associated with chronic kidney disease (CKD) has been recognized over recent years as a powerful independent predictor of cardiovascular (CV) complications which is the main cause of mortality in CKD patients [1–3].
Numerous studies demonstrated the multifactorial causes of anemia in CKD. Some CKD patients have more severe anemia than it would be expected according to their degree of severity of renal insufficiency [4–7]. In these cases, it is necessary to consider other factors that may contribute to the renal anemia, such as inflammation and infection (excessive production of cytokines), effect of drugs (renin-angiotensin-aldosterone system (RAAS) blockers, cytostatics and some others), nutritional disorders (hypoalbuminemia, deficiency of vitamin B12, folic acid, iron) [2, 8, 9]. Chronic inflammation and pro-inflammatory cytokines (IL-1β, TNF-α, INF-γ) are the factors that may aggravate anemia development in patients with diabetes mellitus (DM), as well as in CKD due to systemic diseases (systemic lupus erythematosus (SLE) and systemic vasculitis) [5, 7].
The role of hypoxia inducible factor (HIF) in renal anemia genesis has been better identified. HIF regulates oxygen-sensitive genes’ transcription erythropoietins (EPO gene) and activity of the others important mediators, particularly vascular endothelial growth factor (VEGF), glucose transporters, and nitrogen oxide synthetases [10]. It was studied the relation of HIF with the main iron homeostasis regulator—hepcidin [11]. Active oxygen radicals, which content is always increased in CKD, accelerate HIF degradation and inhibit EPO gene expression, depressing tubular cells adaptation to hypoxia [12]. Hyperglycemia may also lead to HIF degradation and incomplete EPO production, especially in autonomous polyneuropathy in DM [5, 6].
It is discussed the role of lowering sKlotho in CKD anemia that significantly contributes to CV risk increase [13]. Hemoglobin (Hb) levels ≥ 110 g/l was associated with more increased sKlotho levels as a cardiorenoprotective factor in anemia management with epoetin and iron in CKD patients with renal anemia [7, 9].
CKD anemia has normocytic normochromic character. During the course of long-term hemodialysis treatment, anemia may transforms into the hypochromic microcytic iron deficiency anemia due to blood losses and EPO treatment that requires a proper treatment [9, 14].
In recent decades, indications for kidney transplantation have been extended by the taking of high-risk patients (diabetic nephropathy, rapidly progressive glomerulonephritis-RPGN, elderly age) that lead to an increase in the prevalence of post-transplant anemia [15] and increase in CV risk.
If long-term anemia is not completely corrected in CKD patients, eccentric left ventricular hypertrophy (LVH) is formed with developing chronic heart failure (CHF) [1, 16, 17] because of decreased Hb level and an insufficient O2 supply to the tissues leading to the sympathetic nervous system activation, to the increased heartbeat, the renin-angiotensin system and antidiuretic hormone activation, sodium and water retention and edema occurrence, to the increased venous return to heart and the eccentric LVH. In addition, lowering sKlotho leads to increasing serum fibroblast growth factor (FGF-23), which is considered now as a new uremic toxin, which level elevates earlier than parathyroid hormone (PTH) as the progression of the CKD [18, 19]. Increased FGF-23 and lack oxygen supply to cardiomyocytes enhance their apoptosis with the development of myocardial fibrosis and CHF [18, 19].
Early diagnosis of anemia, minimizing and eliminating as much as possible the factors contributing to its development and timely initiation of treatment are considered today as an important strategy to reduce CV and total mortality of patients, to improve their quality of life, and to reduce costs of a hospital treatment of CKD patients with anemia [1, 9, 20, 21]. However, since the publication of the KDIGO ‘Clinical Practice Guideline for Anemia’ in 2012, significant advancement has been achieved in our understanding of anemia mechanisms in CKD including kidney transplant patients. At the same time, there is a burning need for randomized clinical trials for better informed decisions and future optimization of CKD patients care. The aim of the review is to provide a literature summary concerning the early diagnosis and treatment of anemia in CKD and after kidney transplantation, which may be useful for clinicians in their clinical practice.
Literature searches were made in 10 major databases: Pubmed, Medline, Embase, Cochrane Library, CINAHL, e-library, Wiley Online Library, Scopus, Web of Science, and website of WHO ICTRP. The search was carried out to find all articles relevant to CKD and anemia, including diabetes mellitus, systemic diseases and transplant patients, as well as original experimental data. This search encompassed original articles, systematic reviews and meta-analyses. There was no language restriction.
Articles should be full text. Brief publications and abstracts were not included
Research should include at least 20 patients in each group. The minimum mean duration of study was 6 months
Analyzed literature over last 15 years
The article should have the detailed research protocol for assessing of its quality
Patients examination must meet KDIGO 2012 guidelines
Randomized controlled trials
Original experimental data over recent years representing the link of CKD anemia and the markers of cardiovascular risk (cytokines, Klotho, FGF-23, hyperglyceamia, hypoalbuminemia and some others)
Systematic reviews and meta-analyses in this field
A total of 54 references from 562 reviewed articles which met to the search criteria (anemia and CKD, including diabetes mellitus, systemic diseases, and transplanted patients, as well as original experimental data) were selected. The publications included 27 randomized controlled trials, 20 experimental studies representing new data over recent years on the link of the anemia in CKD and the markers of cardiovascular risk (cytokines, Klotho, FGF-23, hyperglycemia, hypoalbuminemia, active oxygen radicals, angiotensin II, interleukin-1,TNF-alpha, NO, and some others), 4 systematic reviews and 3 clinical practice guidelines. There were 10 studies in pre-dialysis patients, 10 in dialysis, and 7 after transplantation among selected studies relevant to the prevention and treatment of anemia in CKD. The main attention was devoted to the analysis of the studies on early diagnosis of anemia, ability to minimize the factors contributing to its severity, timely treatment initiation, that have allowed improving CV and total outcomes, as well as reducing costs of hospital treatment of CKD patients with anemia.
Renal anemia (defined as serum Hb levels <130 g/l for men and <120 g/l for women) is an obligatory complication of CKD progression [1, 2], which is usually occurring when glomerular filtration rate (GFR) decreases below 60 ml/min/1.73 m2 (CKD stage 3–5). At GFR below 43 ml/min/1.73 m2, linear relationship between GFR and Hb level is noted (decreased GFR of 5 ml/min/1.73 m2 is accompanied by a fall in Hb level of 3 g/l) [1, 2, 20]. Importantly, the degree of Hb decreasing is not just a marker of CKD progression, but now, it is considered as also a direct independent predictor of cardiovascular (CV) complications, which are the main causes of mortality in CKD patients [1–3].
Appearance of anemia in CKD may be due to the lowering of endogenous erythropoietin (EPO) production, shortening of the survival time of red blood cells, decreasing in erythroid progenitors receptors’ sensitivity to EPO, and diminution of iron supply to bone marrow because of iron deficiency or its decreased availability, caused mainly by increased levels of hepcidin, due to inflammation accompanying to the chronic uremia [1, 2, 8]. In addition, the pathogenic mechanism of CKD anemia development may involve folate and vitamin B12 deficiency due to malnutrition and chronic inflammation resulting in immature erythroblasts apoptosis [22, 23].
Some CKD patients have more severe anemia than it would be expected according to their degree of renal insufficiency severity [4, 5, 23]. In these patients other factors contributing to the anemia should be considered: inflammation and infection (excess cytokines production), effect of drugs (RAAS blockers, cytostatic agents), nutritional disorders (hypoalbuminemia, vitamin B12, folic acid, iron deficiency). In diabetes mellitus (DM) patients, some other factors may also aggravate anemia: chronic inflammation and pro-inflammatory cytokines (IL-1β, TNF-α, INF-γ), their elevated levels are detected even before the renal failure appearance. Anemia has been found in about 10% of DM patients with normal kidney function [24]. In the cohort of >9000 patients without renal disease, DM was an independent determinant of Hb levels [24]. Many factors have been suggested additionally contributing to the pathogenesis of anemia in DM patients, such as erythropoietin deficiency due to efferent sympathetic denervation of the kidney in diabetic neuropathy, chronic inflammatory reaction leading to functional iron deficiency, non-selective urinary protein excretion leading to transferrin and erythropoietin loss and the use of RAAS blockers [5, 25]. A direct comparison of anemia between matched diabetic and non-diabetic CKD patients in the epidemiologic study which included particularly large number of patients at CKD Stage 3A found out the difference between the groups, and diabetic patients had anemia two times more often than patients without diabetes (60.4 vs 26.4%). Serum ferritin levels, but not iron, were higher in diabetic than in non-diabetic patients at all stages; the first ones had also more severe anemia and the increased ferritin as an acute-phase protein may signify higher subclinical inflammation in diabetic patients [6].
In patients with CKD due to systemic diseases (SLE, systemic vasculitis), anemia in 10–20% of cases also develops at the earlier CKD stages (1–2 stage). It is suggested that exacerbation of glomerulonephritis as well as an underlying systemic disease may lead to cytokine-mediated disorders of erythropoiesis with the development of anemia of chronic disease (ACD). Recognition of the ACD based on the analysis of the features of iron metabolism characterized this form of anemia [7, 9, 23]. The disorders of the iron metabolism are mainly associated with increased iron absorption and retention iron by reticuloendothelial system cells (RES), followed to lowering of iron admission to the bone marrow [7, 23, 26].
In recent years, it has determined the role of hypoxia-inducible factor (HIF) in the genesis of renal anemia [10, 12]. It was found that HIF regulates transcription of oxygen-sensitive genes (EPO gene) and activity of other important mediators, particularly VEGF (vascular endothelial growth factor), glucose transporters, and nitrogen oxide synthetases. HIF is a heterodimer constantly expressed in kidney and consists of alpha and beta subunits. Expression of HIF β-subunit occurs constantly and plays an important role in the body\'s response to xenobiotics when heterodimeric transcription complex with aryl gidrocarbon receptor formed. Expression of α-subunits of HIF-complex (HIF-1α and HIF-2α) is regulated by partial oxygen pressure in tissues. In the case of hypoxia absence, HIF-1α and HIF-2α rapidly degraded. In case of sufficient oxygen supply to tissues, enzyme FIH (factor inhibiting HIF) affects asparagine hydroxylation, thereby preventing increase in transcriptional HIF-1α activity. In case of Hb level fall, α-subunit degradation is inhibited that leads to the formation of HIF-1β—cytochrome P300 complex [10, 22]. As a result, active HIF complex binds to the complementary site of gene EPO locus thereby increasing its production.
Besides hypoxia, transcriptional HIF-1 activation is induced by nitrogen oxide (NO), tumor necrosis factor (TNFα), interleukin-1, and angiotensin II. Thereby, HIF-1 also takes part in the regulation of angiogenesis, glucose, and iron homeostasis [10].
It has been currently established that HIF takes part in EPO production, not only in kidney but also in liver. Liver is also involved in EPO synthesis, but less than kidneys, and extrarenal EPO synthesis cannot compensate its renal production deficiency [27].
The relation of HIF-2α and the main regulator of iron homeostasis—hepcidin has been studied: hypoxia and iron deficiency suppress hepcidin synthesis and thereby increase in the possibility of iron absorption in intestine [11]. It is found that HIF and iron interact by iron-regulated proteins—IRP\'s: IRP-1 and IRP-2. When iron stores in the body decrease, IRP-IRE complex prevents sequestration of transferrin receptor and thereby enhances intracellular intake of iron. If iron stores in the body are sufficient, IRP-IRE complex is inactivated and undergone to protosomal degradation, and iron is not absorbed. Furthermore, HIF-2α post-translationally prevents the development of more severe iron deficiency [10, 22].
Elevating active oxygen radicals in CKD also promotes HIF-1α degradation and inhibits EPO gene expression, thereby decreasing molecular adaptation of tubular cells to hypoxia [12]. Hyperglycemia accompanying to diabetic neuropathy, and especially in case of autonomous polyneuropathy, also leads to HIF-1α degradation and insufficient EPO production [5, 9, 24].
HIF-1α serum content is decreased in CKD patients with anemia (reference ranges are 1.5–6.0 pg/ml in adults and in children older than 14 years and). The murine antiserum and monoclonal antibodies against HIF-1α molecules are used for HIF detection [1, 12].
According to the World Health Organization, criteria for the diagnosis of anemia are [2, 9]:
Hb <130 g/l, Hct < 39%, red blood cell count < 4.0 mln/mcl, in men;
Hb <120 g/l, Hct < 36%, red blood cell count < 3.8 mln/mcl, in women;
Hb <110 g/l, Hct < 33%, in pregnant women.
In CKD patients for the diagnosis and future dynamic anemia control, it is necessary to check: Hb level, main red blood indexes: mean corpuscular volume (MCV), mean cell Hb (MCH), mean cell Hb concentration (MCHC), number of reticulocytes, ferritin level and transferrin saturation (TSAT), serum vitamin B12, and folates, as well as for the other anemia forms [1, 9, 20].
Anemia in CKD is the normocytic and normochromic one. The number of reticulocytes in renal anemia is usually normal or slightly increased that depends on the degree of bone marrow erythropoiesis activity. It is noted increasing of immature reticulocytes fraction (IRF) that representatives of active bone marrow erythropoiesis, despite the EPO deficiency [1, 20, 22]. Perhaps, constant blood loss, associated with hemodialysis procedures, may activates compensatory medullar erythropoiesis. During the long-term hemodialysis, anemia may transforms into hypochromic microcytic iron deficiency anemia due to blood losses or EPO treatment that requires a proper treatment. In case of hypochromic microcytic anemia development, hemoglobin in reticulocytes (Ret-Hb) decreases [14, 28].
Functional iron deficiency for erythropoiesis may be diagnosed using TSAT coefficient, as well as the hypochromic red blood cells percentage (HRS), determined by flow cytometry [1, 9, 20]. A high serum ferritin level in combination with low-transferrin saturation are the evidence of increased hepcidin activity that may often be caused by inflammation, confirmable by increased C-reactive protein (CRP) concentration (more than 50 mg/dl) [8, 23, 29]. If CRP level is high, CKD patient should be examined to detect inflammation (acute infection, active systemic inflammatory disease) and subsequent anti-bacterial and/or anti-inflammatory treatment should be provided before starting EPO therapy [1, 9, 20, 23, 29].
Renal anemia is accompanied by various clinical symptoms (dyspnoa, dizziness, poor appetite, depressed mood, decrease in performance, exercise tolerance, breakdown of cognitive, and sexual functions) and led to poor quality of life, increased hospital admissions, progression of kidney, and CV diseases, and increased mortality. Results of observational studies over last years have been strongly confirmed that Hb decreasing is a direct independent predictor of the eccentric LVH and CHF development (Figure 1), because of the falling of Hb level in blood and accompanied insufficient oxygen supply to tissues lead to sympathetic nervous system activation, increased heart rate, RAAS and antidiuretic hormone activation, sodium and water retention, appearance of edema, increase in venous return to the heart, and eccentric LVH.
The impact of anemia on the LVH and CHF development in patients with CKD and anemia in the absence of its timely correction.
In addition, changing levels of recently identified new cardiovascular CKD markers such as sKlotho and FGF-23 progressively contribute to the cardiac remodeling in CKD especially in anemia persisting due to CKD progression. Increased FGF-23 and insufficient supply of oxygen to cardiomyocytes lead to cell apoptosis, myocardial fibrosis, and CHF [17–19].
It was found that circulating form of Klotho (sKlotho) protein has pleiotropic effects as a humoral factor that protects CV system [13, 30]. Adequate sKlotho expression provides both renal and CV protection. According to our date [31], patients from third stage of CKD have shown a direct linear relation between GFR fall and decreasing in sKlotho level. As it was detected firstly by M. Kuro-o, Klotho is synthesized in kidney tubules. This marker is very sensitive to anemia, oxidative stress, intrarenal increasing of angiotensin II, and inflammation that all take part in reduction of Klotho expression in kidneys [30, 32, 33].
Decrease in serum Klotho may be also a result of inhibition of its extrarenal production. In this regard, it is interesting to know findings of Takeshita et al. [34] that indicate the presence of Klotho gene expression in sinoatrial node and high frequency of sudden cardiac death of mice due to cardiac arrhythmias caused by sinoatrial node’s dysfunction with blocked Klotho gene. It has been also recently found the strong correlation of the sKlotho low level with advancing of vascular calcification and CHF in CKD [35, 36]. In addition, it was shown in mice that loss of Klotho results in reduced MCV and MCH in circulating red blood cells (RBC) as well as the expression of HIF-1α and HIF-2α was significantly attenuated in Klotho−/− mice, resulting in suppression of EPO [37]. At the same time, recent studies have shown that administration of recombinant EPO can induce Klotho expression in the rat nephropathy model [37] and in the preliminary clinic studies [32]. Hb levels ≥ 110 g/l were associated with higher serum sKlotho levels in anemia management by epoetin and iron, in patients with anemia at CKD 3B-4 stages (p < 0.001) [32]. Moreover, transmembrane Klotho is a co-receptor for FGF-23. FGF-23 is considered now as a new uremic toxin in CKD advancing because of its pathogenic action predominantly on the heart in CKD. In a normal state, FGF-23 produced by osteocytes regulates phosphorus, vitamin D, and PTH metabolism. However, as was later shown, an elevated FGF-23 is associated with a high risk of death from cardiovascular events (CVE) [18]. It is believed, the effects of FGF-23 to the heart may be caused by its nonselective binding to FGF-4-receptors in the myocardium due to the significant increasing of serum FGF-23 along with progressive Klotho deficiency (as co-receptor for FGF-23) during CKD progression, especially if anemia persists [18, 19]. The data, obtained in our clinical center, indicate association between FGF-23 and Troponin-I, which may be a result of FGF-23 cardiotoxic effect on the myocardium, leading to the appearance of the detectable serum Troponin-I levels [19].
So, taking into account that hypoxia is an independent factor in reducing sKlotho synthesis in CKD and an urgent need of Klotho for CV protection, CKD patients with anemia who are managed to achieve the target Hb and to keep it within the reference range by EPO and iron therapy would have been expected to save sKlotho production and accompanied significantly lower CV risk [13, 32, 36].
According to the International Guidelines of Kidney Disease Improving Global Outcomes (KDIGO, 2012), treatment of renal anemia with EPO should be begin if Hb level is decreased under 100 g/l in adults and children 12–14 years old [1].
In patients with comorbid diseases (CV diseases, DM, advanced atherosclerosis, malignant tumors) as well as in case of notes on stroke, malignancies in past medical history, the decision about EPO treatment should be made individually and started if Hb level <100 g/l, firstly by iron medication (intravenous or per os) [1, 20, 38]. Preliminary correction of iron deficiency is obligatory requirement for the EPO therapy [1, 9, 20]. The velocity of Hb level decrement, the need for transfusions, response to the previous iron treatment, the severity of anemia symptoms, as well as the patient\'s lifestyle (active professional life, intensive school classes in children) should be taken into account at determining time for starting EPO therapy [20].
The upper limit of Hb reference range is determined as 115 g/l for most of the patients. Hb target level should be reached during 4 months [1, 20].
At predialysis CKD stages, short-acting EPO (epoetin-alfa or beta) is administered to patients subcutaneously at a dose of 50–100 IU/kg per week, it is about 6 thousand IU/week subcutaneously [1, 20, 39, 40] (Figure 2). Subcutaneous administration way of short-acting EPO is considered as a choice because it allows using lower doses and reducing the treatment cost [21]. The studies of pharmacokinetic of EPO show that subcutaneous administration prolongs half-life period of elimination of short-acting EPO (epoetin alfa and epoetin beta) [40].
Algorithm for the treatment of anemia with epoetin α or β by subcutaneous administration of the drug at predialysis stages of CKD.
At starting therapy, the rate of Hb increasing should be maintained at 10–20 g/l a month. Changes of hemoglobin level less than 10 g/L or more than 20 g/L require to gradual EPO dose correction by 25% weekly up (but not more than 720 IU/kg/week) or downward (Figure 2).
The rate of Hb increase >20 g/l per month is undesirable because of increase in risk of thrombosis. In this case, it is necessary to titrate down a total weekly EPO dose by 25–50%. Monitoring Hb level at starting treatment period should be performed every 2 weeks, then once a month. Hb’s concentration change less than 10 g/L requires to gradual EPO dose correction by 25% upward [1, 9, 20, 39].
In CKD patients at stages 3–4, iron supplementation is necessary for prevention of iron deficiency, due to increased needs in iron due to EPO treatment, to achieve and maintain Hb level minimum at 115 g/l during EPO treatment. At the CKD stages 3, iron serum balance might be maintained by iron administration per os, for example, ferrum hydroxides (III) polymaltosate, wherein the dose of dietary iron should be at least 200 mg/day [1, 20, 41].
However, in patients with anemia of chronic diseases, it is a good practice to inject iron intravenously only because of insufficient intestinal absorption and iron retention by RES [1, 23, 26].
In addition, it is necessary to control during treatment the residual renal function (GFR and creatinine blood level in the dynamics), blood pressure (ambulatory blood pressure monitoring), hydration (blood volume), and cardiac hemodynamics. Therefore, low-protein diet with sodium restriction that combined with EPO and antihypertensive therapy may also play an important role in Hb maintenance [1, 9, 20]. The lower increasing in Hb level (less than 10 g/l a month or Hct level less than 0.5% a month) is a sign of insufficient effect of EPO treatment.
The most common cause of insufficient response to EPO is an iron deficiency [1, 20, 26, 42]. Adequate correction of iron deficiency is an important part of anemia treatment in patients at predialysis CKD stages and on dialysis [1, 9, 20]. In case of early successful anemia treatment onset in CKD patients, they are required less EPO doses to achieve the target Hb level at hemodialysis reaching as well as a lower incidence of CV complications [9, 39, 43].
Short-acting EPO can be administered to dialysis patients subcutaneously and intravenously as well, but subcutaneous administration way requires lower doses of EPO [1, 20, 44]. Target Hb level is considered as 100–110 g/l (Hct 30–33%) for the majority of hemodialysis (HD) patients [1, 2, 9, 20]. Dose of 100 IU/kg/week of EPO alfa or beta intravenously or of 60 IU/kg/week of EPO alfa or beta subcutaneously is required to achieve and maintain this target Hb level. Subcutaneous EPO administration 1–2 times a week is a way of choice for anemia correction in patients receiving CAPD treatment because it helps to keep conditions for the formation of a fistula in case of further switching to HD treatment[1, 9, 20]. If patients are undergoing CAPD, and neither subcutaneous nor intravenous EPO administration ways can be used, for example, in children, intraperitoneal administration way to the “dry” abdominal cavity is applied, particularly when higher EPO doses are needed than in case of subcutaneous or intravenous injections. Hb level should be monitored every 4–6 weeks in patients on HD and CAPD [1, 9, 20]. Dialysis patients receiving EPO are required iron supplementation intravenously to achieve and maintain target Hb level, for example iron (III) sucrose, low molecular iron dextran or ferric III-hydroxide olygomaltosate intravenously slowly during the last 2 hours of the dialysis session (200 mg once every two weeks) under control of ferritin blood level [1, 45].
Iron deficiency developing during the EPO treatment requires fast correction, which is possible only in case of intravenous administration way of iron. Optimal and tolerance levels of iron metabolism parameters are presented in the Table 1 (1, 9, 20).
Marker | Optimal level | Tolerance level |
---|---|---|
Ferritin, mcg/l | 200–500 | 100–800 |
Transferrin saturation, % | 30–40 | 20–50 |
Number of hypochromic red blood cells, % | <2.5 | <10 |
Optimal and tolerance levels of the iron metabolism parameters.
Iron deficiency is the most definitive for HD patients [1, 22, 23, 26, 45]. The main reason of its development is blood losses during medical manipulations that could be about 3–4 liters, equivalent to 2 g of iron a year: the blood that remains in the extracorporeal circuit (dialyzer, blood tubing line), blood loss from the puncturing locus, blood loss during catheter use, concealed hemorrhage in the gastrointestinal tract, and blood loss during laboratory studies. Young women require more iron supply than men [1, 20, 28].
Efficiency and safety of intravenous iron medications depend on its molecular weight, dose, and ingredients. Complexes of a low molecular weight, such as a ferrum gluconate, are less stable and faster release iron into plasma. Free iron may catalyze reactive oxygen forms generation, causing of lipid peroxidation and tissue damage. The significant portion of a dose of the such drugs is excreted by kidney in the first 4 hours after drug administration and not used for erythropoiesis [1, 45]. Despite of large molecular weight and strength of iron dextran drugs, its disadvantage is the possibility to increase the risk of allergic reactions. Ferric III—hydroxide olygomaltosate [100 mg/ml, 2 ml №5] is not accompanied by free iron release and does not cause antibodies formation and therefore has a good safety profile [1, 9, 20, 45].
The problem of variability of Hb levels during the period of EPO maintenance therapy is important in clinical practice of anemia treatment in CKD patients [4, 28]. According to retrospective analysis of the results of therapy of 281 dialysis patients by short-acting EPO, 90% of those have shown a cyclical variability of Hb levels by more than 15 g/l during 8 weeks. There were three such fluctuations in average during the 1 year observation. These cycles were characterized by increase in average Hb level up to 130 g/l and going down to 103 g/l, and the most common cause (84% of episodes) of it was the changes of EPO dose, 6 times a year in average [46].
One of approaches of solving this problem may be the administration of long-acting EPOs for renal anemia treatment, in particular, darbepoetin alfa and constant erythropoietin receptor activator—methoxypolyethylene glycol epoetin-beta [1, 20, 47, 48]. The starting dose of darbepoetin alfa is 0.45 mcg/kg/weekly in case of subcutaneous or intravenous administration way. It is allowed subcutaneous administration way of a dose of 0.75 mg/kg biweekly [1, 47]. If the increase in Hb levels is less than 10 g/l in 4 weeks, dose of darbepoetin-alfa should be up-titrated by 25%, while the up-titration should not be more often than once every 4 weeks. During maintenance therapy phase, the EPO administration can be continued once a week or biweekly. Darbepoetin alfa could be introduced subcutaneously once a month of a double maintenance dose once biweekly [1, 9, 20].
Starting dose of methoxypolyethylene glycol epoetin-beta is 1.2 mcg/kg once in 4 weeks subcutaneously (baseline Hb level is not taken into account). In case of increase in Hb level less than 10 g/l in 4 weeks, it is necessary titrating dose up by 50%, in case of increase in Hb level more than 20 g/l the dose should be titrated down by 50%. It is important to note that half life of methoxypolyethylene glycol epoetin beta is 139 hours in case of subcutaneous administration way, that is, 7 times longer than half life of epoetin alfa and 3 times longer than half life of darbepoetin alfa [1, 48].
Studies performed in dialysis centers of Germany and the UK have shown that in case of short-acting EPO switching to the long-acting erythropoiesis stimulating agent-methoxypolyethylene glycol epoetin beta (1 injection once a month) or darbepoetin alfa, medical expenses for anemia treatment have been reduced by 58 and 35%, respectively [21].
New classes of erythropoietin-stimulating agents are currently approved. The phase III study of efficacy and safety of Rosksadustat—an inhibitor of prolyl-4-hydroxylase—enzyme, that accelerates HIF deterioration, is carried out. The drug is administered per os. It was shown in preclinical studies that Roksadustat-activated alfa-subunit of HIF and initiated endogenous dose-related EPO secretion, improved iron utilization, and resolved anti-erythropoetin effects of inflammatory cytokines in renal anemia.
Despite the impressive successes of transplantation over the last 30 years, 60% of all recipients’ deaths occur with a functioning kidney transplant [49, 50]. The cause of death more than a half of these cases is CV complications. In renal transplant recipients, CHF risk factors include DM, age over 65 years, increase in systolic blood pressure, hypoalbuminemia, cytomegalovirus infection, and post-transplant anemia (PTA). There has been an increase in the prevalence of PTA over the recent decades [51]. In addition to the general factors for renal anemia (iron and erythropoietin deficiency), other reasons of PTA are considered [49, 50]:
widening of indications for renal transplantation for high-risks patients (with diabetic nephropathy, RPGN and etc.)
elderly age
renal transplantation from marginal donors
modification of recipient’s immunosuppressive treatment when increased using mycophenolate mofetil, calcineurin inhibitors (tacrolimus, cyclosporine A) and rapamycin that associated with high risk of anemia development.
There are relapsing and permanent course of PTA. PTA is also could be of early and late forms, depending on the time after transplantation [50]. Sixty percent of renal transplant recipients show recurrent PTA episodes associated with decreasing of transplant function (GFR < 60 ml/min, serum creatinine more than 190 mmol/l) as well as with recurrent of acute transplant rejection, re-transplantation, that more common in females, in case of donor’s age is older than 60 years, in iron deficiency (ferritin <100 mg/l), in patients with DM, secondary hyperparathyroidism, obstinate infections accompanying by increased CRP levels more than 50 mg/ml, in cases of combined administration of rapamycin and mycophenolate mofetil (MMF) or in combined administration of RAAS blockers and azathioprine or allopurinol [1, 9, 50].
Permanent PTA is found in 30–40% of adults and in 60–80% of children as renal transplant recipients [51, 52]. Early PTA develops in the first 6 months after transplantation; it occurs in 2–3 times more often than the late form of PTA that develops after the sixth month from transplantation [51, 53]. The incidence of the early severe PTA form is currently high despite the effective correction of renal anemia with EPO drugs during preparation for transplantation (at regular HD) and rapid increase in EPO synthesis in transplant. This is due to a post-operative blood loss, inflammatory complications, and hyperparathyroid osteodystrophy. Three months later after surgical intervention, PTA severity decreases as erythropoiesis in transplant increases. However, 4–5 years later after transplantation, the risk of anemia development increases (late PTA) because of the progressive dysfunction of transplant (due to chronic rejection, sandimmune nephropathy, nephropathy recurrence in the transplant, nephritis de novo in transplant), as well as appearance of the late transplant complications such as persistent infections, cancerous diseases [54]. There is an inverse relationship between creatinine and Hb levels in the most of recipients with late PTA that is typical for CKD in general [1, 20, 53].
Causes of PTA are multifactorial (Table 2) [51], but the basic mechanism of either early or late PTA forms is the fall of endogenous EPO synthesis often associated with the absolute or relative iron deficiency. EPO level increases to the normal values after renal transplantation in case of immediate transplant functioning and decreases in case of its delayed start of function. The frequent reason of PTA is a resistance to EPO appears in case of rejection crisis of transplant as well as in severe secondary hyperparathyroidism and particularly often in iron deficiency [50–53]. The absolute or relative iron deficiency is found in 40–50% of recipients, and it is usually associated with PTA. Post-operative blood loss, chronic infections with increased CRP level, absence of iron stores in recipient, and small-scale blood loss may result in iron deficiency [51].
Anemia pathogenetic mechanism | Causes of the PTA |
---|---|
Iron deficiency | Post-operative blood loss, attenuation of iron stores in case of chronic inflammation, drug-induced erosions of gastrointestinal tract (NSAIDs, glucocorticosteroids) |
Erythropoetin deficiency | Acute injury of transplant due to a long period of thermic ischemia, chronic transplant rejection, ciclosporin nehpropathy |
Resistance to erythropoetin | Recurrent acute transplant rejection crises, severe hyperparathyroidism, protein-energy malnutrition, pure red-cell aplasia (PRCA) |
Disease activity | Systemic disease, bacterial and viral infections |
Malignant tumors | B-cell lymphoma, Kaposi sarcoma, hepatocellular carcinoma |
Drug-induced disorders of erythrogenesis | Cytostatics (azathioprine, MMF, Sirolimus), RAAS blockers, anti-viral medication (ribavirin, ganciclovir) |
Causes of anemia prevalence after kidney transplantation.
Important causes of PTA are the iatrogenic factors that could impair erythropoiesis, iron metabolism, and aggravate resistance to EPO [51, 52]. Decreased response to EPO may be due to the iron deficiency that could be a result of gastrointestinal erosions, accompanying treatment with non-steroid anti-inflammatory drugs, direct and indirect anticoagulants, and corticosteroids [1, 51]. On the other hand, corticosteroids oppose to myelotoxicity of cytostatics, including iatrogenic hypoplastic PTA, due to both a direct stimulating effect on erythropoiesis and granulocytopoiesis and influence on pharmacodynamic of cytostatics [1, 51]. A number of studies have shown the role of RAAS blockers in the PTA pathogenesis. RAAS blockers diminish EPO synthesis due to blocking renin-angiotensin-aldosterone system and increasing serum level of tetrapeptide AcSDKP as endogenous inhibitor of erythropoiesis. The negative effect of RAAS blockers on erythropoiesis is a dose-dependent one. Combined administration of RAAS blocker with azathioprine or allopurinol is the most dangerous for erythropoiesis [1, 20, 51, 53].
High doses of sandimmune that are administered in the first few weeks after transplantation enhance EPO synthesis in tardive functioning transplant due to vasoconstriction and activation of renin-angiotensin-aldosterone system, but it does not lead to increase in hemoglobin level. Long term using of calcineurin inhibitors at late stages of transplantation is often accompanied by such complications as progressive tubulointerstitial fibrosis of transplant (sandimmune nephropathy) with EPO deficiency and PTA progression. Myelotoxic effect of sirolimus (rapamycin) has been found in the majority of studies, and it has been more significant that in case of MMF administration. Upon joining the MMF and sirolimus, PTA develops in 30–57% of cases. The degree of decreased in Hb level was correlated with sirolimus dose. Many of new cytostatics used in transplantation require significant increase in EPO dose due to its aggravation of PTA [1, 9, 51, 53].
Rare PTA forms include an autoimmune PTA, a pure red-cell aplasia (PRCA) with autoantibodies to EPO or to its receptor [54]. PRCA appearance as complication of cytostatic therapy (azathioprine, MMF, tacrolimus) with replication of myelotropic parvovirus B19 manifests severe progressive anemia with absolute resistance to EPO and total dependence on blood transfusions.
In recipients, long-term treated by immunodepressants (including polyclonal and monoclonal anti-lymphocyte antibody and anti-cytokine drugs), iatrogenic PTA may be due to manifestation of infectious (tuberculosis, CMV, HBV, HCV replication) or cancer complications of transplantation: malignant lymphoma, hepatocellular carcinoma, Kaposi’s sarcoma, melanoma, bladder cancer, parathyroid cancer, and cervical cancer [1, 20, 51]. Iatrogenic PTA (with an increase in the requirement of EPO) often develops in the case of treatment of viral hepatitis by ribavirin, ganciclovir.
Risk factors of PTA include depression of transplant function (GFR <60 ml/min, blood creatinine > 190 mmol/l), recurrent relapses of acute transplant rejection, retransplantation, female gender, donor age over 60 years, iron deficiency (ferritin < 100 mcg/l), diabetes mellitus, uremic hyperparathyroidism, persistent infection with increase in CRP levels > 50 mg/mL, combined administration of rapamycin and mycophenolate mofetil (MMF), as well as RAAS blockers and azathioprine or allopurinol [1, 51, 53].
On the other hand, PTA is a risk factor of the acute transplant dysfunction and long-term mortality of recipients [49]. Early anemia may aggravate transplant dysfunction immediately after transplantation [50]. So, early PTA aggravates hypoxia of transplant’s medullary zone, and ischemia-reperfusion syndrome thereby increases in risk of ischemic acute tubular necrosis, acute transplant abruption reaction, acute pyelonephritis and also slows down regeneration of the epithelium of the convoluted tubules in recipients with delayed transplant function [49]. Extra renal manifestations of early PTA include exacerbation of ischemic heart disease, progressive CHF, arrhythmia, prolonged immobilization with a poor exercise activity, blood transfusion complications, and viral infections [50].
Despite of the fact that the late PTA has a moderate degree in 90% of recipients (Hb level is of 110–115 g/l), it could worsen prognosis by increasing risk of long-term cardiac mortality [53]. A number of studies have shown correlation between PTA severity and survival of recipients [15, 49, 50, 53]. The decrement in hemoglobin level by 10 g/l significantly increases the risk of CHF, cardiovascular, and overall mortality. The data have shown that iron deficiency affect the survival rate of recipients. Recipients with diabetic nephropathy and Hct level of more than 30% have significantly lower risk of CV complications than when Hct < 30% [1, 20, 50].
The observational studies over the last years did not confirm a detrimental effect of EPO on transplant function and an increase in risk of thrombosis as suggested in 1980–90s. [1, 2, 9, 20]. In the case of early PTA form, despite of presence of factors that may induce resistance to EPO, there is usually an adequate response to EPO treatment with rapid normalization of Hb levels and improving quality of life. In recent years, more preliminary data have been obtained regarding positive effects of early PTA correction with EPO on transplant’s function and survival, cardiovascular, immune, and endocrine system of recipient [1, 20, 51].
Response to the EPO treatment of PTA may be enhanced significantly by the modification of drug therapy (Table 3): in the case of PRCA, EPO therapy should be cancelled until antibodies to EPO in blood will disappear; in the case of severe hemolysis, the doses of corticosteroids should be increased and plasmapheresis to be carried out [54].
Drugs | Form of anemia | Therapy approach |
---|---|---|
NSAIDs, Glucocorticosteroids | Iron-deficiency | The cancel of NSAID, dose decline of glucocorticosteroids, up-titration of iron agents in the presence of the same epoetin dose |
Rapamycin, MMF | Hypoplastic | Dose decline of Rapamycin, up-titration of epoetins dose |
Azathioprine, MMF, tacrolimus | PRCA | The cancel of cytostatic agents, epoetin and iron agents, high dosage of glucocorticosteroids, plasmapheresis, blood transfusion |
RAAS blockers and Azathioprine, Allopurinol | Hypoplastic | The cancel of Azathioprine, Allopurinol, dose decline of ACE inhibitors, its substitution for Angiotensin II Receptor Blockers, calcium antagonists, β-blockers |
Ribavirin | Hemolytic | Dose decline of Ribavirin, up-titration of epoetin |
The principals of the corrections of iatrogenic PTA.
Precedent data have been received are positive about cardioprotective effect of EPO on regression of LVH according to echocardiography and on improving quality of life that was observed in the case of EPO treatment in recipients with blood creatinine less than 190 mmol/l and hematocrit rising (to the level of 33–36%). Cardioprotective effects of EPO are associated as considered with both antianemic and pleiotropic effects: activation of stem endotheliocytes and myocardial neoangiogenesis, as well as with inhibition of myocardiocytes apoptosis and maintenance of sKlotho levels [1, 16, 32, 43].
In recent years, renal anemia is considered as not only a risk factor for CKD progression but mainly as a separate independent powerful risk factor for CVD that is the main cause of death in CKD patients. It is recognized not only direct pathogenic effects of anemia on CV system due to its association with increased cardiac output, left ventricular hypertrophy, heart failure but also due to contribution to the reduction of cardiorenoprotective factor’s synthesis such as the soluble form of Klotho protein in CKD.
Anemia accompanying CKD in diabetic nephropathy as well as due to systemic diseases occurs earlier than in others patients of CKD populations and requires close attention and control at CKD 2–3a stages.
In dialysis patients along with decreased EPO production and anti-proliferative effects of uremic toxins, chronic immune activation due to the contact of the immune system cells with a dialysis membrane as well as due to frequent episodes of infection, leading to the typical chronic disease anemia, changes of iron metabolism may play a role in the genesis of anemia.
In recent decades, an increase in the prevalence of anemia in patients after kidney transplantation has been due to: expanding indications for renal transplantation for high-risk patients, elderly age, renal transplantation from marginal donors («unideal» donors, a donor over 60 years old or over 50 years old and the cause of death whom was cardiovascular disease), modification of recipient’s immunosuppressive treatment when mycophenolate mofetil, calcineurin inhibitors (tacrolimus, cyclosporine A) and rapamycin, associated with high risk of anemia development are used more often.
Early diagnosis of anemia, minimizing and eliminating the possible factors contributing to its development, and timely initiation of treatment are considered today as an important strategy to reduce CV and total mortality of patients, to improve their quality of life and to reduce costs of a hospital treatment of CKD patients with anemia.
This work was supported by Russian Science Foundation (grant №14-15-00947 2014).
CKD | Chronic Kidney Disease |
CAPD | Continuous Ambulatory Peritoneal Dialysis |
CRP | C-reactive protein |
CHF | Congestive heart failure |
CVC | Cardiovascular complications |
CVE | cardiovascular events |
DM | diabetes mellitus |
EPO | erythropoietin |
eGFR | estimated Glomerular Filtration Rate |
FGF-23 | fibroblast growth factor |
HD | Regular Hemodialysis |
HIF | hypoxia inducible factor |
HRS | hypochromic red blood cells percentage |
LVH | left ventricular hypertrophy |
MCV | mean corpuscular volume |
MCH | mean cell Hb |
MCHC | mean cell hemoglobin concentration |
MMF | mycophenolate mofetil |
PTH | parathyroid hormone |
PTA | Post-transplant anemia |
PRCA | Pure Red-Cell Aplasia |
RCTs | randomized controlled trials |
RAAS | renin-angiotensin-aldosterone system |
RBCs | red blood cells |
SLE | Systemic Lupus Erythematosus |
TSAT | transferrin saturation coefficient |
Book - collection of Works distributed in a book format, whose selection, coordination, preparation, and arrangement has been performed and published by IntechOpen, and in which the Work is included in its entirety in an unmodified form along with one or more other contributions, each constituting separate and independent sections, but together assembled into a collective whole.
",metaTitle:"Attribution Policy",metaDescription:"DEFINITION OF TERMS",metaKeywords:null,canonicalURL:"/page/attribution-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"Work - a book Chapter (as well as Conference Papers), including any and all content, graphics, images and/or other materials forming part of, or accompanying, the Chapter/Conference Paper.
\\n\\nAttribution – appropriate credit for the used Work or book.
\\n\\nCreative Commons licenses – enable licensors to retain copyright while allowing others to use their Works in an appropriate way.
\\n\\nWith the purpose of protecting Authors' copyright and the transparent reuse of OA (Open Access) content, IntechOpen has developed Rules of Attribution of Works licensed under Creative Commons licenses.
\\n\\nIn case you reuse or republish any of the Works licensed under CC licenses, you must abide by the guidelines outlined below:
\\n\\nAll rights to Books and other compilations published on the IntechOpen platform and in print are reserved by IntechOpen. The Copyright to Books and other compilations is subject to a separate Copyright from any that exists in the included Works.
\\n\\nA Book in its entirety or a significant part of a Book cannot be translated freely without specific written consent by the publisher. Further information can be obtained at permissions@intechopen.com.
\\n\\nIn instances where permission is obtained from the publisher for reusing or republishing the Book, or significant parts of the Book, all of the following conditions apply:
\\n\\nEvery single Work that is used has to be attributed in the way described. If you are unsure about proper attribution, please write to permissions@intechopen.com.
\\n\\nIndividual Works originally published in IntechOpen books are licensed under Creative Commons licenses and can be freely used under terms of the respective CC license, if properly attributed. In order to properly attribute the Work you must respect all the conditions outlined below:
\\n\\nEvery single Work that is used has to be attributed in the way as described. If you are unsure about proper attribution, please contact Us at permissions@intechopen.com.
\\n\\nIn the event that you use more than one of IntechOpen's Works published in one or more books (but not a significant part of the book that is under separate Copyright), each of these have to be properly attributed in the way described.
\\n\\nIntechOpen does not have any claims on newly created copyrighted Works, but the Works originally published by IntechOpen must be properly attributed.
\\n\\nAll these rules apply to BOTH online and offline use.
\\n\\nParts of the Rules of Attribution are based on Work Attributing Creative Commons Materials published by the Australian Research Council Centre of Excellence for Creative Industries and Innovation, in partnership with Creative Commons Australia, which can be found at creativecommons.org.au licensed under Creative Commons Attribution 2.5 Australia license, and Best practices for attribution published by Creative Commons, which can be found at wiki.creativecommons.org under the Creative Commons Attribution 4.0 license.
\\n\\nAll the above rules are subject to change, IntechOpen reserves the right to take appropriate action if any of the conditions outlined above are not met.
\\n\\nPolicy last updated: 2016-06-09
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Work - a book Chapter (as well as Conference Papers), including any and all content, graphics, images and/or other materials forming part of, or accompanying, the Chapter/Conference Paper.
\n\nAttribution – appropriate credit for the used Work or book.
\n\nCreative Commons licenses – enable licensors to retain copyright while allowing others to use their Works in an appropriate way.
\n\nWith the purpose of protecting Authors' copyright and the transparent reuse of OA (Open Access) content, IntechOpen has developed Rules of Attribution of Works licensed under Creative Commons licenses.
\n\nIn case you reuse or republish any of the Works licensed under CC licenses, you must abide by the guidelines outlined below:
\n\nAll rights to Books and other compilations published on the IntechOpen platform and in print are reserved by IntechOpen. The Copyright to Books and other compilations is subject to a separate Copyright from any that exists in the included Works.
\n\nA Book in its entirety or a significant part of a Book cannot be translated freely without specific written consent by the publisher. Further information can be obtained at permissions@intechopen.com.
\n\nIn instances where permission is obtained from the publisher for reusing or republishing the Book, or significant parts of the Book, all of the following conditions apply:
\n\nEvery single Work that is used has to be attributed in the way described. If you are unsure about proper attribution, please write to permissions@intechopen.com.
\n\nIndividual Works originally published in IntechOpen books are licensed under Creative Commons licenses and can be freely used under terms of the respective CC license, if properly attributed. In order to properly attribute the Work you must respect all the conditions outlined below:
\n\nEvery single Work that is used has to be attributed in the way as described. If you are unsure about proper attribution, please contact Us at permissions@intechopen.com.
\n\nIn the event that you use more than one of IntechOpen's Works published in one or more books (but not a significant part of the book that is under separate Copyright), each of these have to be properly attributed in the way described.
\n\nIntechOpen does not have any claims on newly created copyrighted Works, but the Works originally published by IntechOpen must be properly attributed.
\n\nAll these rules apply to BOTH online and offline use.
\n\nParts of the Rules of Attribution are based on Work Attributing Creative Commons Materials published by the Australian Research Council Centre of Excellence for Creative Industries and Innovation, in partnership with Creative Commons Australia, which can be found at creativecommons.org.au licensed under Creative Commons Attribution 2.5 Australia license, and Best practices for attribution published by Creative Commons, which can be found at wiki.creativecommons.org under the Creative Commons Attribution 4.0 license.
\n\nAll the above rules are subject to change, IntechOpen reserves the right to take appropriate action if any of the conditions outlined above are not met.
\n\nPolicy last updated: 2016-06-09
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5681},{group:"region",caption:"Middle and South America",value:2,count:5161},{group:"region",caption:"Africa",value:3,count:1683},{group:"region",caption:"Asia",value:4,count:10200},{group:"region",caption:"Australia and Oceania",value:5,count:886},{group:"region",caption:"Europe",value:6,count:15610}],offset:12,limit:12,total:117096},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateendthirdsteppublish",topicid:"25"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:18},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:5},{group:"topic",caption:"Engineering",value:11,count:14},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:5},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:63},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:1},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5126},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Health",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-health",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editedByType:"Edited by",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9523",title:"Oral and Maxillofacial Surgery",subtitle:null,isOpenForSubmission:!1,hash:"5eb6ec2db961a6c8965d11180a58d5c1",slug:"oral-and-maxillofacial-surgery",bookSignature:"Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/9523.jpg",editedByType:"Edited by",editors:[{id:"82453",title:"Dr.",name:"Gokul",middleName:null,surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editedByType:"Edited by",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9018",title:"Some RNA Viruses",subtitle:null,isOpenForSubmission:!1,hash:"a5cae846dbe3692495fc4add2f60fd84",slug:"some-rna-viruses",bookSignature:"Yogendra Shah and Eltayb Abuelzein",coverURL:"https://cdn.intechopen.com/books/images_new/9018.jpg",editedByType:"Edited by",editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",middleName:null,surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editedByType:"Edited by",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9585",title:"Advances in Complex Valvular Disease",subtitle:null,isOpenForSubmission:!1,hash:"ef64f11e211621ecfe69c46e60e7ca3d",slug:"advances-in-complex-valvular-disease",bookSignature:"Michael S. Firstenberg and Imran Khan",coverURL:"https://cdn.intechopen.com/books/images_new/9585.jpg",editedByType:"Edited by",editors:[{id:"64343",title:null,name:"Michael S.",middleName:"S",surname:"Firstenberg",slug:"michael-s.-firstenberg",fullName:"Michael S. Firstenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10150",title:"Smart Manufacturing",subtitle:"When Artificial Intelligence Meets the Internet of Things",isOpenForSubmission:!1,hash:"87004a19de13702d042f8ff96d454698",slug:"smart-manufacturing-when-artificial-intelligence-meets-the-internet-of-things",bookSignature:"Tan Yen Kheng",coverURL:"https://cdn.intechopen.com/books/images_new/10150.jpg",editedByType:"Edited by",editors:[{id:"78857",title:"Dr.",name:"Tan Yen",middleName:null,surname:"Kheng",slug:"tan-yen-kheng",fullName:"Tan Yen Kheng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9386",title:"Direct Numerical Simulations",subtitle:"An Introduction and Applications",isOpenForSubmission:!1,hash:"158a3a0fdba295d21ff23326f5a072d5",slug:"direct-numerical-simulations-an-introduction-and-applications",bookSignature:"Srinivasa Rao",coverURL:"https://cdn.intechopen.com/books/images_new/9386.jpg",editedByType:"Edited by",editors:[{id:"6897",title:"Dr.",name:"Srinivasa",middleName:"P",surname:"Rao",slug:"srinivasa-rao",fullName:"Srinivasa Rao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editedByType:"Edited by",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editedByType:"Edited by",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"326",title:"Food Industry",slug:"food-industry",parent:{title:"Bromatology",slug:"agricultural-and-biological-sciences-bromatology"},numberOfBooks:5,numberOfAuthorsAndEditors:267,numberOfWosCitations:154,numberOfCrossrefCitations:141,numberOfDimensionsCitations:398,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"food-industry",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8174",title:"Current Issues and Challenges in the Dairy Industry",subtitle:null,isOpenForSubmission:!1,hash:"65801e53dbd318f8f50a65e32f6ffcb0",slug:"current-issues-and-challenges-in-the-dairy-industry",bookSignature:"Salam A. Ibrahim, Tahl Zimmerman and Rabin Gyawali",coverURL:"https://cdn.intechopen.com/books/images_new/8174.jpg",editedByType:"Edited by",editors:[{id:"107905",title:"Prof.",name:"Salam",middleName:null,surname:"Ibrahim",slug:"salam-ibrahim",fullName:"Salam Ibrahim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6911",title:"Milk Production, Processing and Marketing",subtitle:null,isOpenForSubmission:!1,hash:"d0b383fbc5e2a2fcc9da5bd58766529d",slug:"milk-production-processing-and-marketing",bookSignature:"Khalid Javed",coverURL:"https://cdn.intechopen.com/books/images_new/6911.jpg",editedByType:"Edited by",editors:[{id:"136829",title:"Dr.",name:"Khalid",middleName:null,surname:"Javed",slug:"khalid-javed",fullName:"Khalid Javed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6074",title:"Technological Approaches for Novel Applications in Dairy Processing",subtitle:null,isOpenForSubmission:!1,hash:"0dfa7481fd3aa113a670d789ca1ae319",slug:"technological-approaches-for-novel-applications-in-dairy-processing",bookSignature:"Nurcan Koca",coverURL:"https://cdn.intechopen.com/books/images_new/6074.jpg",editedByType:"Edited by",editors:[{id:"206952",title:"Prof.",name:"Nurcan",middleName:null,surname:"Koca",slug:"nurcan-koca",fullName:"Nurcan Koca"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5505",title:"Superfood and Functional Food",subtitle:"An Overview of Their Processing and Utilization",isOpenForSubmission:!1,hash:"1c054794ab111a6e0a6bfebeb77baa8e",slug:"superfood-and-functional-food-an-overview-of-their-processing-and-utilization",bookSignature:"Viduranga Waisundara and Naofumi Shiomi",coverURL:"https://cdn.intechopen.com/books/images_new/5505.jpg",editedByType:"Edited by",editors:[{id:"194281",title:"Dr.",name:"Viduranga Yashasvi",middleName:null,surname:"Waisundara",slug:"viduranga-yashasvi-waisundara",fullName:"Viduranga Yashasvi Waisundara"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3424",title:"Food Industry",subtitle:null,isOpenForSubmission:!1,hash:"26d230385a4b7a517b44d60bf75e83de",slug:"food-industry",bookSignature:"Innocenzo Muzzalupo",coverURL:"https://cdn.intechopen.com/books/images_new/3424.jpg",editedByType:"Edited by",editors:[{id:"93139",title:"Dr.",name:"Innocenzo",middleName:null,surname:"Muzzalupo",slug:"innocenzo-muzzalupo",fullName:"Innocenzo Muzzalupo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:5,mostCitedChapters:[{id:"42000",doi:"10.5772/53159",title:"Valorisation of Cheese Whey, a By-Product from the Dairy Industry",slug:"valorisation-of-cheese-whey-a-by-product-from-the-dairy-industry",totalDownloads:6085,totalCrossrefCites:41,totalDimensionsCites:90,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Chiara Mollea, Luca Marmo and Francesca Bosco",authors:[{id:"93865",title:"Dr.",name:"Francesca",middleName:null,surname:"Bosco",slug:"francesca-bosco",fullName:"Francesca Bosco"},{id:"96159",title:"Dr.",name:"Chiara",middleName:null,surname:"Mollea",slug:"chiara-mollea",fullName:"Chiara Mollea"},{id:"166295",title:"Prof.",name:"Luca",middleName:null,surname:"Marmo",slug:"luca-marmo",fullName:"Luca Marmo"}]},{id:"41694",doi:"10.5772/53172",title:"Seaweeds for Food and Industrial Applications",slug:"seaweeds-for-food-and-industrial-applications",totalDownloads:7089,totalCrossrefCites:16,totalDimensionsCites:65,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Berna Kılınç, Semra Cirik, Gamze Turan, Hatice Tekogul and Edis Koru",authors:[{id:"88972",title:"Dr.",name:"Edis",middleName:null,surname:"Koru",slug:"edis-koru",fullName:"Edis Koru"},{id:"161688",title:"Dr.",name:"Berna",middleName:null,surname:"Kılınç",slug:"berna-kilinc",fullName:"Berna Kılınç"}]},{id:"41661",doi:"10.5772/53168",title:"Enzymes in Bakery: Current and Future Trends",slug:"enzymes-in-bakery-current-and-future-trends",totalDownloads:12354,totalCrossrefCites:15,totalDimensionsCites:37,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Ângelo Samir Melim Miguel, Tathiana Souza Martins-Meyer, Érika Veríssimo da Costa Figueiredo, Bianca Waruar Paulo Lobo and Gisela Maria Dellamora-Ortiz",authors:[{id:"97955",title:"Dr.",name:"Gisela Maria",middleName:null,surname:"Dellamora Ortiz",slug:"gisela-maria-dellamora-ortiz",fullName:"Gisela Maria Dellamora Ortiz"},{id:"162156",title:"Dr.",name:"Ângelo Samir",middleName:null,surname:"Melim Miguel",slug:"angelo-samir-melim-miguel",fullName:"Ângelo Samir Melim Miguel"},{id:"162157",title:"MSc.",name:"Tathiana Souza",middleName:null,surname:"Martins Meyer",slug:"tathiana-souza-martins-meyer",fullName:"Tathiana Souza Martins Meyer"},{id:"162158",title:"MSc.",name:"Bianca",middleName:null,surname:"Waruar Lobo",slug:"bianca-waruar-lobo",fullName:"Bianca Waruar Lobo"},{id:"162159",title:"Ms.",name:"Erika Verissimo",middleName:null,surname:"Da Costa Figueiredo",slug:"erika-verissimo-da-costa-figueiredo",fullName:"Erika Verissimo Da Costa Figueiredo"}]}],mostDownloadedChaptersLast30Days:[{id:"41652",title:"Quality Management: Important Aspects for the Food Industry",slug:"quality-management-important-aspects-for-the-food-industry",totalDownloads:7905,totalCrossrefCites:0,totalDimensionsCites:8,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Caroline Liboreiro Paiva",authors:[{id:"95816",title:"Ms.",name:"Caroline",middleName:"Liboreiro",surname:"Paiva",slug:"caroline-paiva",fullName:"Caroline Paiva"}]},{id:"41694",title:"Seaweeds for Food and Industrial Applications",slug:"seaweeds-for-food-and-industrial-applications",totalDownloads:7089,totalCrossrefCites:16,totalDimensionsCites:65,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Berna Kılınç, Semra Cirik, Gamze Turan, Hatice Tekogul and Edis Koru",authors:[{id:"88972",title:"Dr.",name:"Edis",middleName:null,surname:"Koru",slug:"edis-koru",fullName:"Edis Koru"},{id:"161688",title:"Dr.",name:"Berna",middleName:null,surname:"Kılınç",slug:"berna-kilinc",fullName:"Berna Kılınç"}]},{id:"61457",title:"Physico-Chemical Treatment of Dairy Industry Wastewaters: A Review",slug:"physico-chemical-treatment-of-dairy-industry-wastewaters-a-review",totalDownloads:1209,totalCrossrefCites:5,totalDimensionsCites:9,book:{slug:"technological-approaches-for-novel-applications-in-dairy-processing",title:"Technological Approaches for Novel Applications in Dairy Processing",fullTitle:"Technological Approaches for Novel Applications in Dairy Processing"},signatures:"Taner Yonar, Özge Sivrioğlu and Nihan Özengin",authors:[{id:"190012",title:"Associate Prof.",name:"Taner",middleName:null,surname:"Yonar",slug:"taner-yonar",fullName:"Taner Yonar"},{id:"204849",title:"Dr.",name:"Nihan",middleName:null,surname:"Goral",slug:"nihan-goral",fullName:"Nihan Goral"},{id:"207831",title:"Dr.",name:"Özge",middleName:null,surname:"Sivrioğlu",slug:"ozge-sivrioglu",fullName:"Özge Sivrioğlu"}]},{id:"42000",title:"Valorisation of Cheese Whey, a By-Product from the Dairy Industry",slug:"valorisation-of-cheese-whey-a-by-product-from-the-dairy-industry",totalDownloads:6085,totalCrossrefCites:41,totalDimensionsCites:90,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Chiara Mollea, Luca Marmo and Francesca Bosco",authors:[{id:"93865",title:"Dr.",name:"Francesca",middleName:null,surname:"Bosco",slug:"francesca-bosco",fullName:"Francesca Bosco"},{id:"96159",title:"Dr.",name:"Chiara",middleName:null,surname:"Mollea",slug:"chiara-mollea",fullName:"Chiara Mollea"},{id:"166295",title:"Prof.",name:"Luca",middleName:null,surname:"Marmo",slug:"luca-marmo",fullName:"Luca Marmo"}]},{id:"64764",title:"Composition and Properties of Camel Milk",slug:"composition-and-properties-of-camel-milk",totalDownloads:1048,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"milk-production-processing-and-marketing",title:"Milk Production, Processing and Marketing",fullTitle:"Milk Production, Processing and Marketing"},signatures:"Rita Rahmeh, Husam Alomirah, Abrar Akbar and Jiwan Sidhu",authors:[{id:"271007",title:"Dr.",name:"Rita",middleName:null,surname:"Rahmeh",slug:"rita-rahmeh",fullName:"Rita Rahmeh"},{id:"271059",title:"Dr.",name:"Husam",middleName:null,surname:"Alomirah",slug:"husam-alomirah",fullName:"Husam Alomirah"},{id:"271060",title:"Dr.",name:"Jiwan",middleName:null,surname:"Sidhu",slug:"jiwan-sidhu",fullName:"Jiwan Sidhu"},{id:"278685",title:"Dr.",name:"Abrar",middleName:null,surname:"Akbar",slug:"abrar-akbar",fullName:"Abrar Akbar"}]},{id:"52435",title:"Bee Products as Functional Food",slug:"bee-products-as-functional-food",totalDownloads:1953,totalCrossrefCites:0,totalDimensionsCites:3,book:{slug:"superfood-and-functional-food-an-overview-of-their-processing-and-utilization",title:"Superfood and Functional Food",fullTitle:"Superfood and Functional Food - An Overview of Their Processing and Utilization"},signatures:"Banu Yucel, Erkan Topal and Mustafa Kosoglu",authors:[{id:"191429",title:"Prof.",name:"Banu",middleName:null,surname:"Yucel",slug:"banu-yucel",fullName:"Banu Yucel"},{id:"194950",title:"MSc.",name:"Erkan",middleName:null,surname:"Topal",slug:"erkan-topal",fullName:"Erkan Topal"},{id:"194951",title:"MSc.",name:"Mustafa",middleName:null,surname:"Kosoglu",slug:"mustafa-kosoglu",fullName:"Mustafa Kosoglu"}]},{id:"41661",title:"Enzymes in Bakery: Current and Future Trends",slug:"enzymes-in-bakery-current-and-future-trends",totalDownloads:12354,totalCrossrefCites:15,totalDimensionsCites:37,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Ângelo Samir Melim Miguel, Tathiana Souza Martins-Meyer, Érika Veríssimo da Costa Figueiredo, Bianca Waruar Paulo Lobo and Gisela Maria Dellamora-Ortiz",authors:[{id:"97955",title:"Dr.",name:"Gisela Maria",middleName:null,surname:"Dellamora Ortiz",slug:"gisela-maria-dellamora-ortiz",fullName:"Gisela Maria Dellamora Ortiz"},{id:"162156",title:"Dr.",name:"Ângelo Samir",middleName:null,surname:"Melim Miguel",slug:"angelo-samir-melim-miguel",fullName:"Ângelo Samir Melim Miguel"},{id:"162157",title:"MSc.",name:"Tathiana Souza",middleName:null,surname:"Martins Meyer",slug:"tathiana-souza-martins-meyer",fullName:"Tathiana Souza Martins Meyer"},{id:"162158",title:"MSc.",name:"Bianca",middleName:null,surname:"Waruar Lobo",slug:"bianca-waruar-lobo",fullName:"Bianca Waruar Lobo"},{id:"162159",title:"Ms.",name:"Erika Verissimo",middleName:null,surname:"Da Costa Figueiredo",slug:"erika-verissimo-da-costa-figueiredo",fullName:"Erika Verissimo Da Costa Figueiredo"}]},{id:"59827",title:"Ultraviolet Light Applications in Dairy Processing",slug:"ultraviolet-light-applications-in-dairy-processing",totalDownloads:1017,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"technological-approaches-for-novel-applications-in-dairy-processing",title:"Technological Approaches for Novel Applications in Dairy Processing",fullTitle:"Technological Approaches for Novel Applications in Dairy Processing"},signatures:"Nurcan Koca, Müge Urgu and Turkuaz Ecem Saatli",authors:[{id:"206952",title:"Prof.",name:"Nurcan",middleName:null,surname:"Koca",slug:"nurcan-koca",fullName:"Nurcan Koca"},{id:"207388",title:"Dr.",name:"Muge",middleName:null,surname:"Urgu",slug:"muge-urgu",fullName:"Muge Urgu"},{id:"207389",title:"MSc.",name:"Turkuaz Ecem",middleName:null,surname:"Saatli",slug:"turkuaz-ecem-saatli",fullName:"Turkuaz Ecem Saatli"}]},{id:"41685",title:"Yeast: World’s Finest Chef",slug:"yeast-world-s-finest-chef",totalDownloads:2972,totalCrossrefCites:4,totalDimensionsCites:4,book:{slug:"food-industry",title:"Food Industry",fullTitle:"Food Industry"},signatures:"Fábio Faria-Oliveira, Sónia Puga and Célia Ferreira",authors:[{id:"87309",title:"Prof.",name:"Célia",middleName:null,surname:"Ferreira",slug:"celia-ferreira",fullName:"Célia Ferreira"},{id:"95616",title:"Dr.",name:"Fabio",middleName:"Luis Silva",surname:"Faria-Oliveira",slug:"fabio-faria-oliveira",fullName:"Fabio Faria-Oliveira"},{id:"168280",title:"Dr.",name:"Sonia",middleName:null,surname:"Puga",slug:"sonia-puga",fullName:"Sonia Puga"}]},{id:"53092",title:"Functional Pet Foods",slug:"functional-pet-foods",totalDownloads:1275,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"superfood-and-functional-food-an-overview-of-their-processing-and-utilization",title:"Superfood and Functional Food",fullTitle:"Superfood and Functional Food - An Overview of Their Processing and Utilization"},signatures:"Alessandro Di Cerbo, Federica Pezzuto, Gianandrea Guidetti and\nSergio Canello",authors:[{id:"191243",title:"Dr.",name:"Alessandro",middleName:null,surname:"Di Cerbo",slug:"alessandro-di-cerbo",fullName:"Alessandro Di Cerbo"},{id:"191663",title:"Dr.",name:"Federica",middleName:null,surname:"Pezzuto",slug:"federica-pezzuto",fullName:"Federica Pezzuto"},{id:"195028",title:"Dr.",name:"Gianandrea",middleName:null,surname:"Guidetti",slug:"gianandrea-guidetti",fullName:"Gianandrea Guidetti"},{id:"195029",title:"Dr.",name:"Sergio",middleName:null,surname:"Canello",slug:"sergio-canello",fullName:"Sergio Canello"}]}],onlineFirstChaptersFilter:{topicSlug:"food-industry",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/106413/ivo-fridolin",hash:"",query:{},params:{id:"106413",slug:"ivo-fridolin"},fullPath:"/profiles/106413/ivo-fridolin",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()